Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.

Collaborators (21)

Author information

Affiliations

  • 1. From the Clinics for Electrophysiology (C.S., L.B., T.F., M.E.H., M.M., V.S., P.S.), Thoracic and Cardiovascular Surgery (H.F., A.C.-J., R.S., J.G.), and General and Interventional Cardiology-Angiology (V.R.) and the Center for Interdisciplinary Management of Advanced Heart Failure (H.F., A.C.J., R.S., J.G.), Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, the Department of Cardiology, Angiology, and Intensive Care Medicine, Charité Campus Mitte, German Heart Center of Charité-University Medicine Berlin (G.H.), and the Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin (F.K.), Berlin, the Department of Electrophysiology, Heart Center Leipzig, Leipzig (N.D.), and the Department of Cardiology and Angiology, University of Giessen and Kerckhoff Heart Center, Bad Nauheim (S.S.) - all in Germany; the Cardiology Department, Tulane University School of Medicine, New Orleans (N.F.M.); and the Department of Cardiology and Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht (H.J.G.M.C.), and the Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.G.P.T.) - both in the Netherlands.
      Authors
    • Sohns C 1
    • Fox H 1
    • Marrouche NF 1
    • Crijns HJGM 1
    • Costard-Jaeckle A 1
    • Bergau L 1
    • Hindricks G 1
    • Dagres N 1
    • Sossalla S 1
    • Schramm R 1
    • Fink T 1
    • El Hamriti M 1
    • Moersdorf M 1
    • Sciacca V 1
    • Konietschke F 1
    • Rudolph V 1
    • Gummert J 1
    • Tijssen JGP 1
    • Sommer P 1
    (19 authors)

ORCIDs linked to this article

Show all (6)

The New England Journal of Medicine, 27 Aug 2023, 389(15):1380-1389
https://doi.org/10.1056/nejmoa2306037 PMID: 37634135 

A comment on this article appears in "Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation." N Engl J Med. 2023 Dec 28;389(26):2495. A comment on this article appears in "Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation." N Engl J Med. 2023 Dec 28;389(26):2495-2496. A comment on this article appears in "Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. Reply." N Engl J Med. 2023 Dec 28;389(26):2496-2497. Show all (5)

Abstract 

Background

The role of catheter ablation in patients with symptomatic atrial fibrillation and end-stage heart failure is unknown.

Methods

We conducted a single-center, open-label trial in Germany that involved patients with symptomatic atrial fibrillation and end-stage heart failure who were referred for heart transplantation evaluation. Patients were assigned to receive catheter ablation and guideline-directed medical therapy or medical therapy alone. The primary end point was a composite of death from any cause, implantation of a left ventricular assist device, or urgent heart transplantation.

Results

A total of 97 patients were assigned to the ablation group and 97 to the medical-therapy group. The trial was stopped for efficacy by the data and safety monitoring board 1 year after randomization was completed. Catheter ablation was performed in 81 of 97 patients (84%) in the ablation group and in 16 of 97 patients (16%) in the medical-therapy group. After a median follow-up of 18.0 months (interquartile range, 14.6 to 22.6), a primary end-point event had occurred in 8 patients (8%) in the ablation group and in 29 patients (30%) in the medical-therapy group (hazard ratio, 0.24; 95% confidence interval [CI], 0.11 to 0.52; P<0.001). Death from any cause occurred in 6 patients (6%) in the ablation group and in 19 patients (20%) in the medical-therapy group (hazard ratio, 0.29; 95% CI, 0.12 to 0.72). Procedure-related complications occurred in 3 patients in the ablation group and in 1 patient in the medical-therapy group.

Conclusions

Among patients with atrial fibrillation and end-stage heart failure, the combination of catheter ablation and guideline-directed medical therapy was associated with a lower likelihood of a composite of death from any cause, implantation of a left ventricular assist device, or urgent heart transplantation than medical therapy alone. (Funded by Else Kröner-Fresenius-Stiftung; CASTLE-HTx ClinicalTrials.gov number, NCT04649801.).

Full text links 

Read article at publisher's site: https://doi.org/10.1056/nejmoa2306037

Citations & impact 

Impact metrics

49
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/153382577
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/153382577

Article citations

Go to all (49) article citations

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

Clinical Trials

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Else Kröner-Fresenius-Stiftung (1)